StablevaX™ is a breakthrough technology that aims
to resolve a major World Health issue and save lives

Stablepharma is an ethical business with clear commercial opportunities

Stablepharma on COVID-19

In view of recent Government guidelines and impact of Coronavirus, Stablepharma is investigating the current candidates for a COVID-19 vaccine. We believe that our technology could be highly beneficial in the fight against the Covid-19 pandemic now, and in the future.

Our patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. A stabilised vaccine solution that could eradicate the cold chain and enable stockpiling anywhere in the world.

Click here for further information

WHO state that c. 50% of vaccines are wasted due mostly to failures in the cold chain

Stablepharma does not manufacture vaccines, but stands ready to partner with vaccine manufacturers to add our complimentary and enhancing technology to make anti Covid-19 vaccines safe and thermostable information.

The Stablepharma team will continue to work from home and in our laboratory facilities in Europe. We have identified areas which we consider critical to operate and have developed operational continuity plans to ensure we have sufficient resources to keep our R&D work progressing.

We wish to keep our lines of communication open and those needing to contact us are able to do so. Please contact nchild@stablepharma.com

We wish you well during this time of uncertainty but look forward to a positive outcome for all of us.

We have invented a truly disruptive solution that can eliminate the need for refrigeration ('The Cold Chain') and eradicate vaccine wastage once approved

StablevaX™ is the only patented product that stabilises vaccines and complies with WHO protocols

StablevaX™ eliminates the need for refrigeration

StablevaX™ is administered to patients without any change to current practice


StablevaX is a very disruptive technology which has the potential to greatly improve the success of vaccination programmes around the world

Professor Alan Boyd, CEO Boyds Consultants and former President of Faculty of Pharmaceutical Medicine, Royal College of Physicians

I am investing in Stablepharma, half because of the potential impact on World Health, and half because of the investment opportunity

Dr Inga Zaytseva

Vaccines are the most cost-effective health care interventions there are. A dollar spent on a childhood vaccination not only helps save a life, but greatly reduces spending on future healthcare

Ezekiel Jonathan "Zeke" Emanuel - American oncologist and bioethicist and senior fellow at the Centre for American Progress

Vaccines are a miracle; they're fantastic. Anything that makes people hesitate to give their children vaccines according to the recommended schedule creates risk. Risk for the children who don't get vaccinated and risk for other children, some of whom don't have an immune system, so they're benefiting from the fact that the community protection means the disease doesn't get to them

Bill Gates

The best vaccine imaginable is only valuable to the extent we get it to everyone who needs it

Seth Franklin Berkley, M.D., CEO of the GAVI Alliance and a global advocate on the power of vaccines

When you're a large company with significant market share, it's tempting to view market disruptions as a threat, but we view them as an opportunity

John T Chambers, former Chairman & CEO of Cisco Systems

Vaccines are the tugboats of preventive health

William Herbert Foege M.D., M.P.H. is credited with "devising the global strategy that led to the eradication of smallpox in the late 1970s"

It’s rare that most of us get an opportunity to participate in such a worthy project and perhaps leave our thumbprint on the planet, in such a positive way?

Nick Child, MD Stablepharma

Receive our investor information pack

Please enter your details below to receive our investor information pack